NX Development Corp. Is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers

NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This designation was provided for the “real-time detection and visualization of epithelial ovarian tumors during debulking surgery.” Read Full Press Release

The release as fetched from its publisher. photonamic.de ↗